RxDoctor Payments Data

Jay Downey, MD

Family Medicine · San Ysidro, CANPI 1073610960

Payments from drug & device makers

$5,044in general payments, 2019–2025

Across 278 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$998
  • AstraZeneca$670
  • GSK$512
  • Amarin Pharma, Inc.$365
  • Lilly USA, LLC$261
  • Boehringer Ingelheim$246
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,01799%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,044 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$140,786
Medicare patients
348
Services billed
1,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$72,020
EliquisApixaban55$59,706
JanuviaSitagliptin Phosphate43$48,091
TrulicityDulaglutide30$34,305
FarxigaDapagliflozin Propanediol27$25,934
JardianceEmpagliflozin14$21,151
TrintellixVortioxetine Hydrobromide14$17,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,661
MounjaroTirzepatide18$17,460
Breo ElliptaFluticasone/Vilanterol29$15,936
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$10,736
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$8,858
Atorvastatin Calcium805$8,546
Emgality PenGalcanezumab-Gnlm12$8,494
Levothyroxine Sodium519$7,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$72,02073 claims
PfizerEliquis$191$59,70655 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin N$261$54,05972 claims
MerckJanuvia, Dulera$212$51,56354 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$670$37,68655 claims
GSKTrelegy Ellipta, Breo Ellipta$512$33,59854 claims
Boehringer IngelheimJardiance$246$21,15114 claims
AbbVieSynthroid$998$5,96363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in San Ysidro

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →